Intra-articular sodium hyaluronate in osteoarthritis of the knee

Roy D Altman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objectives: Hyaluronan (HA) has recently been approved in the United States for management of pain in osteoarthritis (OA) of the knee and is the first biological available for use in OA. To better understand the therapeutic role of HA, this review focuses on comparative clinical trial data. Methods: Literature reports of clinical trials comparing HA with placebo, non-steroidal anti-inflammatory drugs, and intra-articular corticosteroids were reviewed. The pivotal US trial evaluating HA efficacy and safety was summarized. Results: Over the past decade, 5 of 8 controlled clinical trials demonstrated HA was superior to placebo in relieving the pain of OA. A sixth trial showed improvement in a subset of older patients with more severe disease. Comparison of HA with corticosteroids showed equal pain relief in the first few weeks after therapy, with HA demonstrating more sustained benefit up to 60 days. In the recent US trial, HA was statistically superior to placebo and at least as effective as naproxen in providing analgesia. In all trials reporting adverse effects, the primary adverse effect with HA was pain at the injection site. Conclusions: HA appears effective in relieving the pain of OA of the knee and provides a relatively safe alternative for patients for whom conventional therapy has failed. (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalSeminars in Arthritis and Rheumatism
Volume30
Issue number2 SUPPL. 1
StatePublished - 2000
Externally publishedYes

Fingerprint

Knee Osteoarthritis
Hyaluronic Acid
Joints
Pain
Placebos
Osteoarthritis
Adrenal Cortex Hormones
Clinical Trials
Naproxen
Controlled Clinical Trials
Pain Management
Analgesia
Anti-Inflammatory Agents
Therapeutics
Safety
Injections

Keywords

  • Drug therapy
  • Hyaluronan
  • Osteoarthritis
  • Sodium hyaluronate

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Intra-articular sodium hyaluronate in osteoarthritis of the knee. / Altman, Roy D.

In: Seminars in Arthritis and Rheumatism, Vol. 30, No. 2 SUPPL. 1, 2000, p. 11-18.

Research output: Contribution to journalArticle

Altman, Roy D. / Intra-articular sodium hyaluronate in osteoarthritis of the knee. In: Seminars in Arthritis and Rheumatism. 2000 ; Vol. 30, No. 2 SUPPL. 1. pp. 11-18.
@article{bb439b14f7a64f1f8eedcaeea497773e,
title = "Intra-articular sodium hyaluronate in osteoarthritis of the knee",
abstract = "Objectives: Hyaluronan (HA) has recently been approved in the United States for management of pain in osteoarthritis (OA) of the knee and is the first biological available for use in OA. To better understand the therapeutic role of HA, this review focuses on comparative clinical trial data. Methods: Literature reports of clinical trials comparing HA with placebo, non-steroidal anti-inflammatory drugs, and intra-articular corticosteroids were reviewed. The pivotal US trial evaluating HA efficacy and safety was summarized. Results: Over the past decade, 5 of 8 controlled clinical trials demonstrated HA was superior to placebo in relieving the pain of OA. A sixth trial showed improvement in a subset of older patients with more severe disease. Comparison of HA with corticosteroids showed equal pain relief in the first few weeks after therapy, with HA demonstrating more sustained benefit up to 60 days. In the recent US trial, HA was statistically superior to placebo and at least as effective as naproxen in providing analgesia. In all trials reporting adverse effects, the primary adverse effect with HA was pain at the injection site. Conclusions: HA appears effective in relieving the pain of OA of the knee and provides a relatively safe alternative for patients for whom conventional therapy has failed. (C) 2000 by W.B. Saunders Company.",
keywords = "Drug therapy, Hyaluronan, Osteoarthritis, Sodium hyaluronate",
author = "Altman, {Roy D}",
year = "2000",
language = "English (US)",
volume = "30",
pages = "11--18",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Intra-articular sodium hyaluronate in osteoarthritis of the knee

AU - Altman, Roy D

PY - 2000

Y1 - 2000

N2 - Objectives: Hyaluronan (HA) has recently been approved in the United States for management of pain in osteoarthritis (OA) of the knee and is the first biological available for use in OA. To better understand the therapeutic role of HA, this review focuses on comparative clinical trial data. Methods: Literature reports of clinical trials comparing HA with placebo, non-steroidal anti-inflammatory drugs, and intra-articular corticosteroids were reviewed. The pivotal US trial evaluating HA efficacy and safety was summarized. Results: Over the past decade, 5 of 8 controlled clinical trials demonstrated HA was superior to placebo in relieving the pain of OA. A sixth trial showed improvement in a subset of older patients with more severe disease. Comparison of HA with corticosteroids showed equal pain relief in the first few weeks after therapy, with HA demonstrating more sustained benefit up to 60 days. In the recent US trial, HA was statistically superior to placebo and at least as effective as naproxen in providing analgesia. In all trials reporting adverse effects, the primary adverse effect with HA was pain at the injection site. Conclusions: HA appears effective in relieving the pain of OA of the knee and provides a relatively safe alternative for patients for whom conventional therapy has failed. (C) 2000 by W.B. Saunders Company.

AB - Objectives: Hyaluronan (HA) has recently been approved in the United States for management of pain in osteoarthritis (OA) of the knee and is the first biological available for use in OA. To better understand the therapeutic role of HA, this review focuses on comparative clinical trial data. Methods: Literature reports of clinical trials comparing HA with placebo, non-steroidal anti-inflammatory drugs, and intra-articular corticosteroids were reviewed. The pivotal US trial evaluating HA efficacy and safety was summarized. Results: Over the past decade, 5 of 8 controlled clinical trials demonstrated HA was superior to placebo in relieving the pain of OA. A sixth trial showed improvement in a subset of older patients with more severe disease. Comparison of HA with corticosteroids showed equal pain relief in the first few weeks after therapy, with HA demonstrating more sustained benefit up to 60 days. In the recent US trial, HA was statistically superior to placebo and at least as effective as naproxen in providing analgesia. In all trials reporting adverse effects, the primary adverse effect with HA was pain at the injection site. Conclusions: HA appears effective in relieving the pain of OA of the knee and provides a relatively safe alternative for patients for whom conventional therapy has failed. (C) 2000 by W.B. Saunders Company.

KW - Drug therapy

KW - Hyaluronan

KW - Osteoarthritis

KW - Sodium hyaluronate

UR - http://www.scopus.com/inward/record.url?scp=0033785080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785080&partnerID=8YFLogxK

M3 - Article

C2 - 11071577

AN - SCOPUS:0033785080

VL - 30

SP - 11

EP - 18

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 2 SUPPL. 1

ER -